Medizinischer Rat für internationale Kommunikation (IOMC) |

GET THE APP

Extrait/Indexé dans

Ouvrez la porte J, Génamique, Google Scholar, ISA (résumés scientifiques indiens), Base de données CAS (Chemical Abstract Services), CABI (Royaume-Uni), Index Copernic, Hinar, EBSCO, Répertoire des périodiques d'Ulrich, Pesticides botaniques , Résumés de mauvaises herbes, AgBiotechNet, Ressource VetMed, Résumés de physiologie des cultures, Abrégés d'agroforesterie, Résumés helminthologiques, Horticulture ornementale, Abrégés de phytogénétiques, Novelles and informations on the porc, Abrégés sur les sciences laitières, Basis der Données sur Landwirtschaftliche Wirtschaft, Basis für Parasitologie-Studien, CAB-Lebensläufe, Zoologisches Register, Neue und nachträgliche Informationen, Basis für Ernährungs- und Lebensmittelwissenschaften, Basis für biologische Forschung, Weltgesundheit, ABC Chimie, Zentrum des Wissenschaften,SCIMAGO ist ein Zug,der viele andere Charaktere verrät.

article de recherche

Deficits in Processing Speed and Decision Making in Relapsing-Remitting Multiple Sclerosis: The Digit Clock Drawing Test (dCDT)

David J. Libon, Dana L. Penney, Randal Davis, David S. Tabby, Joel Eppig, Christine Nieves, Aaron Bloch, Jacqueline B. Donohue, Laura Brennan, Katherine L. Rife, Graham Wicas, Melissa Lamar, Catherine C. Price, Rhoda Au, Rod Swenson, and Kelly Davis Garrett, on behalf of the Clock Sketch Consortium

The current research assessed how digital clock drawing test (dCDT) parameters compliment and convey additional information in conjunction with traditional clock drawing scoring..Voir plus»

Communication courtoise

Massive Osteolysis of maxilla, Diagnosis by exclusion: A case report

Bhavana Murjani

Gorham-Stout malady additionally known as as vanishing bone malady could be a rare entity poignant the animal material. Proliferation of plant tissue with destruction of bone st..Voir plus»

Série de cas

177Lu-PSMA Therapy an Alternative Therapy for Metastatic Castrate Resistant Prostate Cancer with Suboptimal Response: Are we ready for it

Sharifa Al Sheebani, Ajda Altinoz*, Lutfi A Kurban, Saadia Ibrahim, Gehad Nassar, Hussam Sadaqa, Jawaher A Ansari, Sulaman R Magdub, Sahar Mohsin, Iram Syed, Aftab Bhatti and Rizwan Syed

Introduction: Lutetium-177-PSMA-617 (177Lu-PSMA) is used as the last treatment option in metastatic castrate resistant prostate cancer (mCRPC). We p..Voir plus»